Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract Extraction | 72 | 2022 | 127 | 13.900 |
Why?
|
| Lens Implantation, Intraocular | 84 | 2022 | 152 | 13.010 |
Why?
|
| Cataract | 68 | 2022 | 134 | 12.260 |
Why?
|
| Lenses, Intraocular | 43 | 2022 | 96 | 6.300 |
Why?
|
| Visual Acuity | 53 | 2022 | 236 | 5.070 |
Why?
|
| Vision Screening | 13 | 2023 | 40 | 4.420 |
Why?
|
| Aphakia, Postcataract | 26 | 2022 | 36 | 4.210 |
Why?
|
| Refraction, Ocular | 17 | 2020 | 61 | 3.540 |
Why?
|
| Amblyopia | 12 | 2023 | 43 | 3.200 |
Why?
|
| Pseudophakia | 19 | 2022 | 27 | 2.980 |
Why?
|
| Infant | 74 | 2022 | 2891 | 2.660 |
Why?
|
| Postoperative Complications | 38 | 2022 | 1615 | 2.630 |
Why?
|
| Child, Preschool | 66 | 2022 | 3187 | 2.570 |
Why?
|
| Ophthalmology | 13 | 2022 | 39 | 2.530 |
Why?
|
| Axial Length, Eye | 11 | 2021 | 15 | 2.510 |
Why?
|
| Child | 82 | 2023 | 6405 | 2.440 |
Why?
|
| Lens Capsule, Crystalline | 17 | 2012 | 39 | 2.390 |
Why?
|
| Phacoemulsification | 18 | 2020 | 69 | 2.190 |
Why?
|
| Posterior Capsule of the Lens | 6 | 2015 | 6 | 2.140 |
Why?
|
| Biometry | 10 | 2021 | 72 | 2.130 |
Why?
|
| Capsulorhexis | 16 | 2012 | 18 | 1.860 |
Why?
|
| Lens, Crystalline | 7 | 2015 | 39 | 1.710 |
Why?
|
| Refractive Errors | 5 | 2023 | 24 | 1.520 |
Why?
|
| Eye | 9 | 2021 | 89 | 1.500 |
Why?
|
| Optics and Photonics | 7 | 2016 | 29 | 1.410 |
Why?
|
| Vitrectomy | 15 | 2018 | 21 | 1.370 |
Why?
|
| Prospective Studies | 32 | 2023 | 3705 | 1.360 |
Why?
|
| Intraocular Pressure | 10 | 2020 | 143 | 1.340 |
Why?
|
| Humans | 144 | 2023 | 68618 | 1.330 |
Why?
|
| Contact Lenses | 7 | 2020 | 14 | 1.320 |
Why?
|
| Triamcinolone Acetonide | 4 | 2012 | 10 | 1.240 |
Why?
|
| Follow-Up Studies | 31 | 2022 | 3259 | 1.180 |
Why?
|
| Glucocorticoids | 4 | 2020 | 222 | 1.170 |
Why?
|
| Male | 88 | 2021 | 37321 | 1.130 |
Why?
|
| Exotropia | 2 | 2021 | 9 | 1.070 |
Why?
|
| Adolescent | 41 | 2022 | 8912 | 1.040 |
Why?
|
| Oculomotor Muscles | 7 | 2022 | 54 | 1.030 |
Why?
|
| Anterior Chamber | 5 | 2010 | 20 | 1.020 |
Why?
|
| Retrospective Studies | 43 | 2022 | 7277 | 1.010 |
Why?
|
| Intraoperative Complications | 12 | 2016 | 129 | 0.990 |
Why?
|
| Esotropia | 3 | 2021 | 13 | 0.990 |
Why?
|
| Strabismus | 7 | 2022 | 37 | 0.990 |
Why?
|
| Glaucoma | 9 | 2022 | 50 | 0.990 |
Why?
|
| Female | 76 | 2021 | 38074 | 0.980 |
Why?
|
| Acrylic Resins | 9 | 2011 | 48 | 0.970 |
Why?
|
| Microphthalmos | 3 | 2015 | 9 | 0.960 |
Why?
|
| Aphakia | 4 | 2022 | 7 | 0.960 |
Why?
|
| Capsule Opacification | 2 | 2015 | 2 | 0.920 |
Why?
|
| Vitreous Body | 5 | 2012 | 26 | 0.880 |
Why?
|
| Hyperopia | 4 | 2023 | 14 | 0.870 |
Why?
|
| Myopia | 4 | 2022 | 27 | 0.850 |
Why?
|
| Postoperative Period | 11 | 2019 | 238 | 0.830 |
Why?
|
| Immersion | 1 | 2021 | 10 | 0.800 |
Why?
|
| Lens Subluxation | 3 | 2012 | 3 | 0.790 |
Why?
|
| Cornea | 8 | 2022 | 76 | 0.770 |
Why?
|
| Retinoscopy | 7 | 2016 | 11 | 0.740 |
Why?
|
| Reproducibility of Results | 13 | 2019 | 2077 | 0.720 |
Why?
|
| Predictive Value of Tests | 10 | 2020 | 1465 | 0.720 |
Why?
|
| Lens Diseases | 4 | 2010 | 5 | 0.710 |
Why?
|
| Corneal Diseases | 3 | 2015 | 12 | 0.710 |
Why?
|
| Treatment Outcome | 28 | 2021 | 7029 | 0.700 |
Why?
|
| Endothelium, Corneal | 3 | 2012 | 20 | 0.700 |
Why?
|
| Persistent Hyperplastic Primary Vitreous | 3 | 2018 | 4 | 0.680 |
Why?
|
| Surgeons | 1 | 2020 | 68 | 0.670 |
Why?
|
| Prostheses and Implants | 2 | 2012 | 159 | 0.640 |
Why?
|
| Vision Disorders | 5 | 2018 | 94 | 0.630 |
Why?
|
| Ehlers-Danlos Syndrome | 2 | 2015 | 13 | 0.610 |
Why?
|
| Forecasting | 1 | 2019 | 277 | 0.610 |
Why?
|
| Anisometropia | 3 | 2023 | 12 | 0.580 |
Why?
|
| Risk Factors | 14 | 2020 | 5731 | 0.580 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2015 | 504 | 0.570 |
Why?
|
| Posterior Capsulotomy | 2 | 2016 | 2 | 0.550 |
Why?
|
| Developmental Disabilities | 1 | 2017 | 119 | 0.550 |
Why?
|
| Eye Injuries | 2 | 2015 | 18 | 0.530 |
Why?
|
| Ophthalmologic Surgical Procedures | 7 | 2022 | 32 | 0.530 |
Why?
|
| Academies and Institutes | 5 | 2021 | 31 | 0.520 |
Why?
|
| Lidocaine | 3 | 2003 | 36 | 0.490 |
Why?
|
| Contrast Sensitivity | 1 | 2014 | 28 | 0.480 |
Why?
|
| Eye Abnormalities | 2 | 2014 | 15 | 0.480 |
Why?
|
| Anesthetics, Local | 3 | 2003 | 83 | 0.460 |
Why?
|
| Vision, Ocular | 1 | 2013 | 68 | 0.440 |
Why?
|
| Hyaluronic Acid | 3 | 2003 | 206 | 0.440 |
Why?
|
| Sclerostomy | 2 | 2012 | 3 | 0.430 |
Why?
|
| Infant, Newborn | 14 | 2020 | 2455 | 0.430 |
Why?
|
| Models, Animal | 5 | 2006 | 252 | 0.420 |
Why?
|
| Corneal Endothelial Cell Loss | 1 | 2012 | 2 | 0.420 |
Why?
|
| Ocular Hypertension | 1 | 2012 | 43 | 0.410 |
Why?
|
| Sclera | 1 | 2012 | 8 | 0.410 |
Why?
|
| Sensitivity and Specificity | 6 | 2023 | 1753 | 0.400 |
Why?
|
| Tonometry, Ocular | 5 | 2020 | 11 | 0.400 |
Why?
|
| Endophthalmitis | 2 | 2010 | 15 | 0.390 |
Why?
|
| Uveitis, Anterior | 2 | 2012 | 15 | 0.370 |
Why?
|
| Preoperative Period | 4 | 2015 | 50 | 0.370 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2010 | 19 | 0.370 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2010 | 19 | 0.370 |
Why?
|
| Tomography, Optical Coherence | 3 | 2020 | 88 | 0.370 |
Why?
|
| Angelman Syndrome | 1 | 2010 | 2 | 0.370 |
Why?
|
| Aqueous Humor | 1 | 2010 | 51 | 0.370 |
Why?
|
| Incidence | 9 | 2019 | 1603 | 0.370 |
Why?
|
| Enoxaparin | 2 | 2012 | 51 | 0.360 |
Why?
|
| Astigmatism | 2 | 2023 | 17 | 0.360 |
Why?
|
| Silicone Elastomers | 3 | 2007 | 17 | 0.360 |
Why?
|
| Iris Diseases | 2 | 2007 | 8 | 0.360 |
Why?
|
| Young Adult | 10 | 2022 | 5717 | 0.350 |
Why?
|
| Equipment Design | 9 | 2020 | 500 | 0.350 |
Why?
|
| Accommodation, Ocular | 2 | 2021 | 9 | 0.350 |
Why?
|
| Video Games | 1 | 2010 | 39 | 0.350 |
Why?
|
| Intraoperative Care | 1 | 2010 | 91 | 0.350 |
Why?
|
| Reoperation | 9 | 2019 | 467 | 0.340 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2020 | 10 | 0.320 |
Why?
|
| Case-Control Studies | 6 | 2022 | 1553 | 0.310 |
Why?
|
| Ultrasonography | 4 | 2021 | 453 | 0.300 |
Why?
|
| Vision, Binocular | 4 | 2021 | 30 | 0.300 |
Why?
|
| Software | 1 | 2010 | 418 | 0.300 |
Why?
|
| Technology Assessment, Biomedical | 3 | 2021 | 24 | 0.290 |
Why?
|
| Optic Disk | 2 | 2020 | 37 | 0.290 |
Why?
|
| Eye Movements | 3 | 2022 | 44 | 0.280 |
Why?
|
| Retinal Ganglion Cells | 2 | 2020 | 72 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 931 | 0.280 |
Why?
|
| Ciliary Body | 3 | 2018 | 52 | 0.270 |
Why?
|
| Health Care Surveys | 1 | 2007 | 239 | 0.270 |
Why?
|
| Prosthesis Implantation | 1 | 2007 | 83 | 0.270 |
Why?
|
| Cysts | 1 | 2006 | 70 | 0.270 |
Why?
|
| Adult | 16 | 2022 | 21403 | 0.260 |
Why?
|
| Disease Management | 2 | 2018 | 248 | 0.260 |
Why?
|
| Rubella Syndrome, Congenital | 2 | 2015 | 2 | 0.250 |
Why?
|
| Pediatrics | 2 | 2011 | 341 | 0.250 |
Why?
|
| Aged | 14 | 2021 | 14862 | 0.240 |
Why?
|
| Acrylates | 1 | 2004 | 17 | 0.240 |
Why?
|
| Nystagmus, Pathologic | 2 | 2022 | 12 | 0.230 |
Why?
|
| Professional Practice | 1 | 2003 | 47 | 0.220 |
Why?
|
| Age Factors | 4 | 2010 | 1864 | 0.220 |
Why?
|
| Prevalence | 5 | 2018 | 1619 | 0.220 |
Why?
|
| False Positive Reactions | 3 | 2018 | 95 | 0.220 |
Why?
|
| Photorefractive Keratectomy | 1 | 2022 | 12 | 0.210 |
Why?
|
| Fibrinolytic Agents | 1 | 2006 | 377 | 0.210 |
Why?
|
| Ectopia Lentis | 1 | 2022 | 4 | 0.210 |
Why?
|
| Foreign-Body Migration | 1 | 2002 | 38 | 0.200 |
Why?
|
| Aging | 4 | 2012 | 911 | 0.200 |
Why?
|
| Myopia, Degenerative | 2 | 2014 | 2 | 0.200 |
Why?
|
| United States | 9 | 2021 | 7367 | 0.200 |
Why?
|
| Orthoptics | 1 | 2021 | 3 | 0.200 |
Why?
|
| Ocular Motility Disorders | 1 | 2021 | 15 | 0.190 |
Why?
|
| Suture Techniques | 1 | 2021 | 75 | 0.190 |
Why?
|
| Neuromuscular Agents | 1 | 2021 | 22 | 0.190 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2020 | 2 | 0.190 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2011 | 85 | 0.190 |
Why?
|
| Nasolacrimal Duct | 1 | 2020 | 4 | 0.190 |
Why?
|
| Dacryocystorhinostomy | 1 | 2020 | 5 | 0.190 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2021 | 31 | 0.190 |
Why?
|
| Macular Edema | 2 | 2018 | 21 | 0.180 |
Why?
|
| Referral and Consultation | 3 | 2020 | 383 | 0.180 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 120 | 0.180 |
Why?
|
| Rabbits | 5 | 2004 | 509 | 0.180 |
Why?
|
| Ketorolac | 1 | 2020 | 11 | 0.180 |
Why?
|
| Optic Nerve Diseases | 1 | 2020 | 31 | 0.180 |
Why?
|
| Papilledema | 1 | 2020 | 21 | 0.180 |
Why?
|
| Drug Combinations | 4 | 2006 | 304 | 0.180 |
Why?
|
| Fluorescein Angiography | 1 | 2020 | 57 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 772 | 0.180 |
Why?
|
| Dexamethasone | 1 | 2020 | 150 | 0.180 |
Why?
|
| Staining and Labeling | 3 | 2012 | 144 | 0.170 |
Why?
|
| Prognosis | 5 | 2019 | 2093 | 0.170 |
Why?
|
| Smartphone | 1 | 2020 | 69 | 0.170 |
Why?
|
| Uveal Diseases | 1 | 2018 | 1 | 0.160 |
Why?
|
| Time Factors | 8 | 2019 | 4655 | 0.160 |
Why?
|
| Eye Diseases | 2 | 2009 | 38 | 0.160 |
Why?
|
| Operating Rooms | 1 | 2019 | 108 | 0.160 |
Why?
|
| Lasers, Solid-State | 2 | 2015 | 8 | 0.150 |
Why?
|
| Anesthesia | 1 | 2019 | 120 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2012 | 4848 | 0.150 |
Why?
|
| Retinopathy of Prematurity | 1 | 2017 | 34 | 0.140 |
Why?
|
| Neurologic Examination | 1 | 2017 | 107 | 0.140 |
Why?
|
| Physical Examination | 1 | 2018 | 152 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2017 | 43 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2018 | 249 | 0.140 |
Why?
|
| Corneal Pachymetry | 1 | 2015 | 5 | 0.130 |
Why?
|
| Middle Aged | 11 | 2020 | 21147 | 0.130 |
Why?
|
| Delphi Technique | 1 | 2015 | 62 | 0.130 |
Why?
|
| Echothiophate Iodide | 1 | 2015 | 1 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 240 | 0.130 |
Why?
|
| Intraoperative Period | 2 | 2012 | 62 | 0.130 |
Why?
|
| Fovea Centralis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Disease Progression | 2 | 2010 | 1038 | 0.120 |
Why?
|
| Scleral Diseases | 1 | 2014 | 1 | 0.120 |
Why?
|
| Eye Protective Devices | 1 | 2014 | 4 | 0.120 |
Why?
|
| Mesopic Vision | 1 | 2014 | 1 | 0.120 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2015 | 58 | 0.120 |
Why?
|
| Color Vision | 1 | 2014 | 2 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2007 | 403 | 0.120 |
Why?
|
| Skin Abnormalities | 1 | 2014 | 11 | 0.120 |
Why?
|
| Minerals | 2 | 2006 | 43 | 0.120 |
Why?
|
| Prosthesis Fitting | 1 | 2014 | 6 | 0.120 |
Why?
|
| Point Mutation | 1 | 2014 | 97 | 0.120 |
Why?
|
| Sodium Chloride | 2 | 2006 | 136 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 159 | 0.120 |
Why?
|
| Acetates | 2 | 2006 | 74 | 0.120 |
Why?
|
| Scanning Laser Polarimetry | 1 | 2013 | 1 | 0.120 |
Why?
|
| Corneal Transplantation | 1 | 2013 | 3 | 0.110 |
Why?
|
| Corneal Edema | 1 | 2013 | 4 | 0.110 |
Why?
|
| Corneal Stroma | 1 | 2013 | 20 | 0.110 |
Why?
|
| Prosthesis Design | 4 | 2019 | 301 | 0.110 |
Why?
|
| Siblings | 1 | 2013 | 34 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2014 | 235 | 0.110 |
Why?
|
| Joint Instability | 1 | 2014 | 87 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 492 | 0.110 |
Why?
|
| Therapeutic Irrigation | 3 | 2012 | 63 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2013 | 737 | 0.110 |
Why?
|
| England | 2 | 2003 | 64 | 0.110 |
Why?
|
| Trypan Blue | 2 | 2003 | 24 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1140 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 438 | 0.110 |
Why?
|
| Coloring Agents | 2 | 2003 | 66 | 0.100 |
Why?
|
| Polymethyl Methacrylate | 2 | 2002 | 31 | 0.100 |
Why?
|
| Diplopia | 2 | 2010 | 14 | 0.100 |
Why?
|
| History, 20th Century | 2 | 2003 | 248 | 0.100 |
Why?
|
| Eye Enucleation | 1 | 2012 | 6 | 0.100 |
Why?
|
| Microscopy | 1 | 2012 | 64 | 0.100 |
Why?
|
| Cell Count | 1 | 2012 | 248 | 0.100 |
Why?
|
| Microscopy, Acoustic | 1 | 2011 | 4 | 0.100 |
Why?
|
| Prosthesis Failure | 2 | 2002 | 130 | 0.100 |
Why?
|
| Viscosupplements | 1 | 2010 | 2 | 0.090 |
Why?
|
| Water | 2 | 2002 | 230 | 0.090 |
Why?
|
| Intravitreal Injections | 1 | 2010 | 16 | 0.090 |
Why?
|
| Depth Perception | 1 | 2010 | 12 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 100 | 0.090 |
Why?
|
| Injections | 1 | 2010 | 119 | 0.090 |
Why?
|
| Graves Ophthalmopathy | 1 | 2010 | 4 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2014 | 753 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2011 | 274 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2013 | 458 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 320 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2021 | 402 | 0.090 |
Why?
|
| Decompression, Surgical | 1 | 2010 | 55 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 109 | 0.090 |
Why?
|
| Rupture, Spontaneous | 2 | 2006 | 21 | 0.080 |
Why?
|
| Eyeglasses | 1 | 2009 | 11 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 507 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1054 | 0.080 |
Why?
|
| Macula Lutea | 1 | 2008 | 6 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2006 | 236 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 498 | 0.080 |
Why?
|
| Animals | 6 | 2006 | 20881 | 0.080 |
Why?
|
| India | 3 | 2014 | 41 | 0.080 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2007 | 8 | 0.070 |
Why?
|
| Nerve Fibers | 2 | 2020 | 77 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 186 | 0.070 |
Why?
|
| Iris | 1 | 2006 | 27 | 0.070 |
Why?
|
| Costa Rica | 2 | 2017 | 6 | 0.070 |
Why?
|
| Nephritis, Hereditary | 1 | 2006 | 8 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2010 | 1342 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2007 | 275 | 0.060 |
Why?
|
| Algorithms | 1 | 2011 | 1196 | 0.060 |
Why?
|
| Health Surveys | 1 | 2007 | 489 | 0.060 |
Why?
|
| Swine | 1 | 2006 | 672 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1266 | 0.060 |
Why?
|
| Retina | 2 | 2003 | 252 | 0.060 |
Why?
|
| Occlusive Dressings | 1 | 2003 | 7 | 0.060 |
Why?
|
| Vision, Monocular | 1 | 2003 | 7 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 2003 | 431 | 0.060 |
Why?
|
| Mitomycin | 1 | 2003 | 27 | 0.050 |
Why?
|
| Anthraquinones | 1 | 2003 | 18 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2003 | 127 | 0.050 |
Why?
|
| Lasers, Excimer | 1 | 2022 | 10 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2020 | 1738 | 0.050 |
Why?
|
| Lenses | 1 | 2002 | 2 | 0.050 |
Why?
|
| Nylons | 1 | 2002 | 9 | 0.050 |
Why?
|
| Miniaturization | 1 | 2002 | 21 | 0.050 |
Why?
|
| Dissection | 1 | 2002 | 29 | 0.050 |
Why?
|
| Polyvinyls | 1 | 2002 | 24 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 529 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 541 | 0.050 |
Why?
|
| Drainage | 1 | 2003 | 133 | 0.050 |
Why?
|
| Posture | 1 | 2022 | 107 | 0.050 |
Why?
|
| Polypropylenes | 1 | 2002 | 31 | 0.050 |
Why?
|
| Antimetabolites | 1 | 2002 | 17 | 0.050 |
Why?
|
| Sutures | 1 | 2021 | 32 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2021 | 8 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 44 | 0.050 |
Why?
|
| Device Removal | 4 | 2003 | 100 | 0.050 |
Why?
|
| Macular Degeneration | 1 | 2002 | 75 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2002 | 130 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 2279 | 0.050 |
Why?
|
| Home Care Services | 1 | 2021 | 84 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2020 | 61 | 0.050 |
Why?
|
| Fundus Oculi | 1 | 2020 | 33 | 0.050 |
Why?
|
| Pupil | 1 | 2020 | 51 | 0.040 |
Why?
|
| Orbit | 1 | 2020 | 30 | 0.040 |
Why?
|
| Reference Values | 2 | 2013 | 579 | 0.040 |
Why?
|
| Video Recording | 2 | 2011 | 145 | 0.040 |
Why?
|
| Vision Tests | 1 | 2019 | 18 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 236 | 0.040 |
Why?
|
| Inflammation | 1 | 2006 | 1030 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 392 | 0.040 |
Why?
|
| Schools | 1 | 2020 | 156 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 378 | 0.040 |
Why?
|
| Pain Management | 1 | 2020 | 186 | 0.040 |
Why?
|
| Sensory Deprivation | 1 | 2018 | 5 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 214 | 0.040 |
Why?
|
| Global Health | 1 | 2018 | 136 | 0.040 |
Why?
|
| Body Weights and Measures | 2 | 2007 | 11 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 733 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 122 | 0.030 |
Why?
|
| Lens Cortex, Crystalline | 2 | 2007 | 2 | 0.030 |
Why?
|
| Lens Nucleus, Crystalline | 2 | 2007 | 2 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 2800 | 0.030 |
Why?
|
| Rubella virus | 1 | 2014 | 2 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 211 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 172 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 110 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 2013 | 25 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2012 | 47 | 0.030 |
Why?
|
| Corneal Opacity | 1 | 2011 | 3 | 0.030 |
Why?
|
| Homocystinuria | 1 | 2011 | 2 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1851 | 0.020 |
Why?
|
| Marfan Syndrome | 1 | 2011 | 42 | 0.020 |
Why?
|
| Nepal | 1 | 2010 | 12 | 0.020 |
Why?
|
| Observer Variation | 1 | 2011 | 330 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 2011 | 120 | 0.020 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2009 | 4 | 0.020 |
Why?
|
| Laser Therapy | 1 | 2009 | 54 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2358 | 0.020 |
Why?
|
| Prolapse | 1 | 2007 | 7 | 0.020 |
Why?
|
| Ophthalmic Solutions | 1 | 2007 | 39 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2007 | 57 | 0.020 |
Why?
|
| Epinephrine | 1 | 2007 | 103 | 0.020 |
Why?
|
| Fetal Growth Retardation | 1 | 2007 | 56 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 255 | 0.020 |
Why?
|
| Urban Population | 1 | 2007 | 255 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 295 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1420 | 0.020 |
Why?
|
| Viscosity | 1 | 2003 | 72 | 0.010 |
Why?
|
| Electron Probe Microanalysis | 1 | 2002 | 16 | 0.010 |
Why?
|
| Fibrosis | 1 | 2004 | 371 | 0.010 |
Why?
|
| Drug Implants | 1 | 2002 | 19 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2004 | 247 | 0.010 |
Why?
|
| Hydrogels | 1 | 2002 | 54 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2002 | 208 | 0.010 |
Why?
|